Evogene Stock Price, News & Analysis

Evogene Ltd. (NASDAQ: EVGN) reported its financial results for Q4 and full year 2021, showing an operating loss of $31 million, up from $24.8 million in 2020. The company maintains a solid cash position of approximately $54 million, aiding its subsidiaries in product development. Key achievements include Biomica's clearance for a phase I immuno-oncology study and Canonic's commercial sales of cannabis products. Looking ahead, Evogene targets 2022 milestones such as launching new products and expanding R&D activities.

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the upcoming World Agri-Tech Innovation Summit on March 22-23, 2022, in San Francisco. This summit has established itself as a pivotal event for the global agtech ecosystem, bringing together growers, agribusiness leaders, technology pioneers, and investors. Key executives from Evogene, including CEO Ofer Haviv and other senior management from its subsidiaries, will be present to explore partnerships and insights. Evogene leverages cutting-edge computational biology to innovate in various life-science industries.

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the 34th Annual ROTH Conference in Dana Point, California, from March 13-15, 2022. CEO Ofer Haviv will host a live fireside chat on March 15 at 12pm PT, along with one-on-one meetings with investors. The conference includes various presentations and panels, attracting institutional investors and analysts. Evogene's innovative technologies, such as MicroBoost AI and GeneRator AI, are focused on life-science product development.

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the appointment of Professor Itamar Grotto to its Board of Directors. Grotto, formerly of the Israeli Ministry of Health, brings extensive expertise in medical cannabis reform. His role aims to bolster Canonic's mission of developing medical cannabis products targeting specific medical indications. Grotto believes in the potential of Canonic to enhance patient care and expressed eagerness to contribute to the company's growth. CEO Arnon Heyman welcomed Grotto, emphasizing his valuable experience for advancing Canonic's strategic goals.

Evogene Ltd. (NASDAQ: EVGN) is set to release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. Following the announcement, management will host a conference call at 09:00 AM Eastern time to discuss these results. The call can be accessed via phone or live webcast on the company's website. Evogene leverages advanced computational biology technologies to enhance life-science product development across various sectors including therapeutics and ag-chemicals.

Evogene Ltd. (NASDAQ-GM: EVGN) will present an overview at the Aegis Capital Corp. Virtual Conference from February 23 to 25, 2022. The presentation is set for February 25 at 9:00 AM EST. Interested participants can access the presentation upon request to Aegis or view the slide deck on Evogene's website. Evogene is a computational biology company aiming to innovate product development in life sciences, using its Computational Predictive Biology platform.

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the shipment of its first batch of cannabis varieties to Portugal after receiving export approval from the Israeli Ministry of Health and Ministry of Agriculture. This shipment is part of Canonic's preparations for a planned commercial launch in Europe in 2023, focusing on developing medical cannabis products using its Computational Predictive Biology platform. The shipped cannabis varieties will undergo lab testing and regulatory examination to comply with European regulations.

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Edison Group's Global Healthcare Open House Event from January 25-27, 2022. The event will take place virtually, and Evogene's presentation will be available on demand starting at 7 AM ET on January 27. Attendees can also register for 1x1 meetings with the company. Evogene utilizes its Computational Predictive Biology platform to advance product pipelines in various life-science sectors, including human health and agriculture.

Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced positive outcomes in pre-clinical studies focused on inflammation and pain relief involving specific cannabis varieties. Conducted by Hadassah Medical Center and Migal - Galilee Research Institute, these studies support Canonic's Precise product line aimed at medical cannabis. The company has filed a patent application for these cannabis varieties. The first products are projected for release in Israel in 2023, with plans to expand into Europe, as the medical cannabis market is expected to exceed €1 billion in Europe this year.